{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:44:34Z","timestamp":1789764274969,"version":"4.0.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Huntington\u2019s disease (HD) is caused by a CAG repeat expansion in the huntingtin (<jats:italic>HTT<\/jats:italic>) gene. CRISPR-Cas9 nuclease causes double-strand breaks (DSBs) in the targeted DNA that induces toxicity, whereas CRISPR interference (CRISPRi) using dead Cas9 (dCas9) suppresses the target gene expression without DSBs. Delivery of dCas9-sgRNA targeting CAG repeat region does not damage the targeted DNA in HEK293T cells containing CAG repeats. When this study investigates whether CRISPRi can suppress mutant HTT (<jats:italic>mHTT<\/jats:italic>), CRISPRi results in reduced expression of mHTT with relative preservation of the wild-type HTT in human HD fibroblasts. Although both dCas9 and Cas9 treatments reduce mHTT by sgRNA targeting the CAG repeat region, CRISPRi delays behavioral deterioration and protects striatal neurons against cell death in HD mice. Collectively, CRISPRi can delay disease progression by suppressing <jats:italic>mHtt<\/jats:italic>, suggesting DNA DSB-free CRISPRi is a potential therapy for HD that can compensate for the shortcoming of CRISPR-Cas9 nuclease.<\/jats:p>","DOI":"10.1038\/s42003-023-04829-8","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T14:03:09Z","timestamp":1682690589000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["DNA double-strand break-free CRISPR interference delays Huntington\u2019s disease progression in mice"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8489-7972","authenticated-orcid":false,"given":"Jung Hwa","family":"Seo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Hong","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daesik","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-Yeon","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bae-Geun","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8997-448X","authenticated-orcid":false,"given":"Jinu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4693-738X","authenticated-orcid":false,"given":"Hyongbum Henry","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1429-2684","authenticated-orcid":false,"given":"Sung-Rae","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,28]]},"reference":[{"key":"4829_CR1","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/ng0893-398","volume":"4","author":"SE Andrew","year":"1993","unstructured":"Andrew, S. E. et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington\u2019s disease. Nat. Genet. 4, 398\u2013403 (1993).","journal-title":"Nat. Genet."},{"key":"4829_CR2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes.","year":"1993","unstructured":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. The Huntington\u2019s Disease Collaborative Research Group. Cell 72, 971\u2013983 (1993).","journal-title":"Cell"},{"key":"4829_CR3","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1056\/NEJMc1910544","volume":"381","author":"SI Sheikh","year":"2019","unstructured":"Sheikh, S. I. & Guerciolini, R. Targeting huntingtin in patients with Huntington\u2019s disease. N. Engl. J. Med. 381, 1181 (2019).","journal-title":"N. Engl. J. Med."},{"key":"4829_CR4","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1590\/0004-282x20190092","volume":"77","author":"L Bayliss","year":"2019","unstructured":"Bayliss, L. et al. Theory of mind impairment in Huntington\u2019s disease patients and their relatives. Arq. Neuropsiquiatr. 77, 574\u2013578 (2019).","journal-title":"Arq. Neuropsiquiatr."},{"key":"4829_CR5","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.7150\/ijbs.9898","volume":"10","author":"L Scheuing","year":"2014","unstructured":"Scheuing, L., Chiu, C. T., Liao, H. M., Linares, G. R. & Chuang, D. M. Preclinical and clinical investigations of mood stabilizers for Huntington\u2019s disease: what have we learned? Int. J. Biol. Sci. 10, 1024\u20131038 (2014).","journal-title":"Int. J. Biol. Sci."},{"key":"4829_CR6","doi-asserted-by":"publisher","first-page":"786","DOI":"10.4103\/1673-5374.156978","volume":"10","author":"T Liu","year":"2015","unstructured":"Liu, T., Im, W., Mook-Jung, I. & Kim, M. MicroRNA-124 slows down the progression of Huntington\u2019s disease by promoting neurogenesis in the striatum. Neural Regen. Res. 10, 786\u2013791 (2015).","journal-title":"Neural Regen. Res."},{"key":"4829_CR7","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.expneurol.2009.03.004","volume":"217","author":"MS Lombardi","year":"2009","unstructured":"Lombardi, M. S. et al. A majority of Huntington\u2019s disease patients may be treatable by individualized allele-specific RNA interference. Exp. Neurol. 217, 312\u2013319 (2009).","journal-title":"Exp. Neurol."},{"key":"4829_CR8","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1089\/hum.2007.116","volume":"19","author":"PH van Bilsen","year":"2008","unstructured":"van Bilsen, P. H. et al. Identification and allele-specific silencing of the mutant huntingtin allele in Huntington\u2019s disease patient-derived fibroblasts. Hum. Gene Ther. 19, 710\u2013719 (2008).","journal-title":"Hum. Gene Ther."},{"key":"4829_CR9","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S1474-4422(17)30280-6","volume":"16","author":"EJ Wild","year":"2017","unstructured":"Wild, E. J. & Tabrizi, S. J. Therapies targeting DNA and RNA in Huntington\u2019s disease. Lancet Neurol. 16, 837\u2013847 (2017).","journal-title":"Lancet Neurol."},{"key":"4829_CR10","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.neuron.2019.01.039","volume":"101","author":"SJ Tabrizi","year":"2019","unstructured":"Tabrizi, S. J., Ghosh, R. & Leavitt, B. R. Huntingtin lowering strategies for disease modification in Huntington\u2019s disease. Neuron 101, 801\u2013819 (2019).","journal-title":"Neuron"},{"key":"4829_CR11","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/d41573-021-00088-6","volume":"20","author":"K Kingwell","year":"2021","unstructured":"Kingwell, K. Double setback for ASO trials in Huntington disease. Nat. Rev. Drug Disco. 20, 412\u2013413 (2021).","journal-title":"Nat. Rev. Drug Disco."},{"key":"4829_CR12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1385\/MN:28:3:259","volume":"28","author":"A Reiner","year":"2003","unstructured":"Reiner, A., Dragatsis, I., Zeitlin, S. & Goldowitz, D. Wild-type huntingtin plays a role in brain development and neuronal survival. Mol. Neurobiol. 28, 259\u2013276 (2003).","journal-title":"Mol. Neurobiol."},{"key":"4829_CR13","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/0092-8674(95)90542-1","volume":"81","author":"J Nasir","year":"1995","unstructured":"Nasir, J. et al. Targeted disruption of the Huntington\u2019s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81, 811\u2013823 (1995).","journal-title":"Cell"},{"key":"4829_CR14","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/0896-6273(95)90346-1","volume":"14","author":"M DiFiglia","year":"1995","unstructured":"DiFiglia, M. et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 14, 1075\u20131081 (1995).","journal-title":"Neuron"},{"key":"4829_CR15","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1126\/science.1059581","volume":"293","author":"C Zuccato","year":"2001","unstructured":"Zuccato, C. et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington\u2019s disease. Science 293, 493\u2013498 (2001).","journal-title":"Science"},{"key":"4829_CR16","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/s41591-019-0478-3","volume":"25","author":"B Zeitler","year":"2019","unstructured":"Zeitler, B. et al. Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington\u2019s disease. Nat. Med. 25, 1131\u20131142 (2019).","journal-title":"Nat. Med."},{"key":"4829_CR17","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1172\/JCI92087","volume":"127","author":"S Yang","year":"2017","unstructured":"Yang, S. et al. CRISPR\/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington\u2019s disease. J. Clin. Invest. 127, 2719\u20132724 (2017).","journal-title":"J. Clin. Invest."},{"key":"4829_CR18","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.omtn.2019.07.009","volume":"17","author":"FK Ekman","year":"2019","unstructured":"Ekman, F. K. et al. CRISPR-Cas9-mediated genome editing increases lifespan and improves motor deficits in a Huntington\u2019s disease mouse model. Mol. Ther. Nucleic Acids 17, 829\u2013839 (2019).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"4829_CR19","first-page":"4566","volume":"25","author":"JW Shin","year":"2016","unstructured":"Shin, J. W. et al. Permanent inactivation of Huntington\u2019s disease mutation by personalized allele-specific CRISPR\/Cas9. Hum. Mol. Genet. 25, 4566\u20134576 (2016).","journal-title":"Hum. Mol. Genet."},{"key":"4829_CR20","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.tips.2018.06.005","volume":"39","author":"D Carroll","year":"2018","unstructured":"Carroll, D. p53 throws CRISPR a curve. Trends Pharm. Sci. 39, 783\u2013784 (2018).","journal-title":"Trends Pharm. Sci."},{"key":"4829_CR21","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41591-018-0049-z","volume":"24","author":"E Haapaniemi","year":"2018","unstructured":"Haapaniemi, E., Botla, S., Persson, J., Schmierer, B. & Taipale, J. CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response. Nat. Med. 24, 927\u2013930 (2018).","journal-title":"Nat. Med."},{"key":"4829_CR22","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.molmed.2018.06.010","volume":"24","author":"M Foronda","year":"2018","unstructured":"Foronda, M. & Dow, L. E. CRISPR: stressed about p53? Trends Mol. Med. 24, 731\u2013733 (2018).","journal-title":"Trends Mol. Med."},{"key":"4829_CR23","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1016\/j.ymthe.2018.04.017","volume":"26","author":"AM Moreno","year":"2018","unstructured":"Moreno, A. M. et al. In situ gene therapy via AAV-CRISPR-Cas9-mediated targeted gene regulation. Mol. Ther. 26, 1818\u20131827 (2018).","journal-title":"Mol. Ther."},{"key":"4829_CR24","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.3390\/ijms21072329","volume":"21","author":"CF Peddle","year":"2020","unstructured":"Peddle, C. F., Fry, L. E., McClements, M. E. & MacLaren, R. E. CRISPR interference-potential application in retinal disease. Int. J. Mol. Sci. 21, 2329 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"4829_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/srep05405","volume":"4","author":"Y Zhang","year":"2014","unstructured":"Zhang, Y. et al. Comparison of non-canonical PAMs for CRISPR\/Cas9-mediated DNA cleavage in human cells. Sci. Rep. 4, 5405 (2014).","journal-title":"Sci. Rep."},{"key":"4829_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20650-x","volume":"12","author":"GW Goldberg","year":"2021","unstructured":"Goldberg, G. W. et al. Engineered dual selection for directed evolution of SpCas9 PAM specificity. Nat. Commun. 12, 349 (2021).","journal-title":"Nat. Commun."},{"key":"4829_CR27","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.gene.2012.07.068","volume":"509","author":"JL Spence","year":"2012","unstructured":"Spence, J. L. & Wallihan, S. Computational prediction of the polyQ and CAG repeat spinocerebellar ataxia network based on sequence identity to untranslated regions. Gene 509, 273\u2013281 (2012).","journal-title":"Gene"},{"key":"4829_CR28","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3727\/096368914X678454","volume":"23","author":"HC Fan","year":"2014","unstructured":"Fan, H. C. et al. Polyglutamine (PolyQ) diseases: genetics to treatments. Cell Transpl. 23, 441\u2013458 (2014).","journal-title":"Cell Transpl."},{"key":"4829_CR29","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nmeth.3284","volume":"12","author":"D Kim","year":"2015","unstructured":"Kim, D. et al. Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells. Nat. Methods 12, 237\u2013243 (2015).","journal-title":"Nat. Methods"},{"key":"4829_CR30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nrn.2015.2","volume":"17","author":"M Heidenreich","year":"2016","unstructured":"Heidenreich, M. & Zhang, F. Applications of CRISPR-Cas systems in neuroscience. Nat. Rev. Neurosci. 17, 36\u201344 (2016).","journal-title":"Nat. Rev. Neurosci."},{"key":"4829_CR31","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","volume":"157","author":"PD Hsu","year":"2014","unstructured":"Hsu, P. D., Lander, E. S. & Zhang, F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 157, 1262\u20131278 (2014).","journal-title":"Cell"},{"key":"4829_CR32","doi-asserted-by":"publisher","first-page":"7473","DOI":"10.1093\/nar\/gku402","volume":"42","author":"Y Lin","year":"2014","unstructured":"Lin, Y. et al. CRISPR\/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences. Nucleic Acids Res. 42, 7473\u20137485 (2014).","journal-title":"Nucleic Acids Res."},{"key":"4829_CR33","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/nbt.2647","volume":"31","author":"PD Hsu","year":"2013","unstructured":"Hsu, P. D. et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat. Biotechnol. 31, 827\u2013832 (2013).","journal-title":"Nat. Biotechnol."},{"key":"4829_CR34","doi-asserted-by":"publisher","first-page":"e28409","DOI":"10.1371\/journal.pone.0028409","volume":"6","author":"RM Cowin","year":"2011","unstructured":"Cowin, R. M. et al. Onset and progression of behavioral and molecular phenotypes in a novel congenic R6\/2 line exhibiting intergenerational CAG repeat stability. PLoS ONE 6, e28409 (2011).","journal-title":"PLoS ONE"},{"key":"4829_CR35","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","volume":"87","author":"L Mangiarini","year":"1996","unstructured":"Mangiarini, L. et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493\u2013506 (1996).","journal-title":"Cell"},{"key":"4829_CR36","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1093\/hmg\/dds037","volume":"21","author":"MA Pouladi","year":"2012","unstructured":"Pouladi, M. A. et al. Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice. Hum. Mol. Genet. 21, 2219\u20132232 (2012).","journal-title":"Hum. Mol. Genet."},{"key":"4829_CR37","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1007\/s13311-012-0112-2","volume":"9","author":"ME Ehrlich","year":"2012","unstructured":"Ehrlich, M. E. Huntington\u2019s disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease. Neurotherapeutics 9, 270\u2013284 (2012).","journal-title":"Neurotherapeutics"},{"key":"4829_CR38","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.neuron.2014.05.032","volume":"83","author":"JL Plotkin","year":"2014","unstructured":"Plotkin, J. L. et al. Impaired TrkB receptor signaling underlies corticostriatal dysfunction in Huntington\u2019s disease. Neuron 83, 178\u2013188 (2014).","journal-title":"Neuron"},{"key":"4829_CR39","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1750-1326-6-71","volume":"6","author":"A Giralt","year":"2011","unstructured":"Giralt, A., Carreton, O., Lao-Peregrin, C., Martin, E. D. & Alberch, J. Conditional BDNF release under pathological conditions improves Huntington\u2019s disease pathology by delaying neuronal dysfunction. Mol. Neurodegener. 6, 71 (2011).","journal-title":"Mol. Neurodegener."},{"key":"4829_CR40","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1093\/bioinformatics\/btu048","volume":"30","author":"S Bae","year":"2014","unstructured":"Bae, S., Park, J. & Kim, J. S. Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics 30, 1473\u20131475 (2014).","journal-title":"Bioinformatics"},{"key":"4829_CR41","doi-asserted-by":"publisher","first-page":"e0165290","DOI":"10.1371\/journal.pone.0165290","volume":"11","author":"YH Won","year":"2016","unstructured":"Won, Y. H. et al. Elucidation of relevant neuroinflammation mechanisms using gene expression profiling in patients with amyotrophic lateral sclerosis. PLoS ONE 11, e0165290 (2016).","journal-title":"PLoS ONE"},{"key":"4829_CR42","doi-asserted-by":"publisher","first-page":"e0156038","DOI":"10.1371\/journal.pone.0156038","volume":"11","author":"MS Kim","year":"2016","unstructured":"Kim, M. S. et al. Differential expression of extracellular matrix and adhesion molecules in fetal-origin amniotic epithelial cells of preeclamptic pregnancy. PLoS ONE 11, e0156038 (2016).","journal-title":"PLoS ONE"},{"key":"4829_CR43","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/nbt.3609","volume":"34","author":"D Kim","year":"2016","unstructured":"Kim, D. et al. Genome-wide analysis reveals specificities of Cpf1 endonucleases in human cells. Nat. Biotechnol. 34, 863\u2013868 (2016).","journal-title":"Nat. Biotechnol."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-023-04829-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-023-04829-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-023-04829-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T15:07:20Z","timestamp":1682694440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-023-04829-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,28]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4829"],"URL":"https:\/\/doi.org\/10.1038\/s42003-023-04829-8","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,28]]},"assertion":[{"value":"18 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"466"}}